By the Top Tier Newswire AI Desk · August 26, 2026 at 1:08 PM ET · reviewed against 16 wire stories
BIOHAVEN LTD (BHVN) is up +15.92% in the latest session. Our newswire has captured 16 stories on BHVN across 10 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why BHVN stock is up today
Biohaven Pharmaceutical (BHVN) surged 15.92% to $16.67 in a volatile session driven by a major licensing deal and a favorable court ruling. The stock opened with a 9.6% gap up and reached a session high of $16.79 before settling near that level. The move reflects growing investor optimism over the company's Kv7 platform and its potential monetization.
What Happened
Biohaven signed a licensing agreement with SK Biopharmaceuticals granting the latter exclusive worldwide rights to Biohaven’s Kv7 platform and its lead epilepsy drug, opakalim. The deal is worth up to $795 million, with Biohaven receiving $400 million upfront and additional royalties. This licensing milestone marks a significant step in monetizing the company’s intellectual property.
In addition, a federal court awarded Biohaven and Yale University $4 million in a trade secret misappropriation case involving RA Capital and Avilar Therapeutics. The ruling reinforces the strength of Biohaven’s intellectual property and adds to the company’s recent positive momentum. Analysts at TD Cowen and Morgan Stanley have maintained or raised their price targets, with RBC Capital raising its target to $23.
What The Data Shows
The stock is trading within its 52-week range of $7.48 to $18.57, having printed 41 fresh 52-week highs on August 26. The session saw heavy volume of 6.4 million shares, more than 2.5 times the 3-month average. The stock opened at $15.76 and briefly dipped to $13.00 before recovering. With a market cap of $2.1 billion and a beta of 3.16, BHVN remains highly volatile and speculative.
What To Watch
Investors should monitor the upcoming obesity trial readout for further catalysts. Analyst coverage and price targets will also be key to watch as the stock continues to attract attention in the market.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Biohaven stock holds Buy rating at TD Cowen after SK deal
Biohaven stock holds Buy rating at TD Cowen after SK deal
17d agoMarketChameleonBULLISH 63General
Biohaven Awarded $4 Million Following Landmark Trade Secret Ruling—What Does This Mean for Investors?
A federal court’s $4 million ruling in favor of Biohaven and Yale University, following a trade secret misappropriation case involving RA Capital and Avilar Therapeutics, signals a potential boost in Biohaven’s positioning and future growth. Here’s what investors should know about the outcome and its implications.
Raymond James cuts Biohaven stock price target on asset monetization
Raymond James cuts Biohaven stock price target on asset monetization
17d agoThe FlyBEARISH 34Analyst
Biohaven price target lowered to $30 from $50 at Raymond James
17d agoInvesting.com MarketsBEARISH 38General
Why is Biohaven Pharmaceutical stock sliding today?
Why is Biohaven Pharmaceutical stock sliding today?
17d agoInvestorsHubBULLISH 69Product/PR
Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal
Biohaven shares rise 7% after licensing its Kv7 platform and epilepsy candidate opakalim to SK Biopharmaceuticals in a deal worth up to $795 million plus royalties.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →